The Aesthetics and Dermatology Device Companies
Aesthetics is cash-pay, consumer-driven medical sales. The major aesthetic and dermatology device and injectable companies, from Allergan and Galderma to the energy-device makers.
*Publishing note for launch: every company name below (shown in bold) should link to its Vocari platform company page.*
Aesthetics does not look like the rest of medical sales. The patients pay cash, demand moves with consumer confidence and social media, and the customers are dermatologists, plastic surgeons, and med spas rather than hospitals. It is also growing fast, with the device market alone on track from about $22 billion toward $38 billion by 2029.
Here are the companies that define aesthetics and dermatology, and what makes selling in it a different game.
What makes aesthetics sales different?
It is a consumer business wearing a medical coat. Because most procedures are elective and cash-pay, demand is driven by consumer sentiment and marketing rather than insurance coverage, and the sale often includes helping a practice grow its own patient demand. The buyers are private practices and med spas, not health systems.
That changes the rep's job. You are selling capital equipment and recurring consumables like injectables, and often selling business growth, not just a device.
Who leads aesthetics and dermatology?
The category splits between injectables and energy devices:
- AbbVie, through Allergan Aesthetics, is the dominant force, home to Botox Cosmetic, the Juvederm fillers, and CoolSculpting, though its roughly $4.9 billion aesthetics business softened in 2025.
- Galderma is the fast-rising pure-play, growing to about $5.2 billion on Restylane, Dysport, and Sculptra.
- Merz Aesthetics rounds out the big three injectable and energy players, with Xeomin, Radiesse, and Ultherapy.
- Establishment Labs is a fast-growing challenger in breast aesthetics with its Motiva implants, up about 27 percent to $211 million.
On the energy side, names like Candela (a leader in laser hair removal), InMode (radiofrequency platforms like Morpheus8), Solta Medical (Thermage and Fraxel), and Sciton (BBL and laser resurfacing) supply the devices.
Which aesthetics companies are growing, and which are struggling?
The category is bifurcating. Galderma and Establishment Labs are growing double digits, while some incumbents cooled: AbbVie's aesthetics segment declined about 6 percent in 2025, and energy specialist InMode slid to about $370 million in a soft capital-equipment year. A few names, like Cutera, went through financial distress and restructuring.
For a rep, that split matters: the growing franchises are hiring and expanding, while the capital-equipment side is more cyclical, rising and falling with how freely practices are buying big machines.
Is aesthetics a good place to sell?
It can be energizing and lucrative, especially in the recurring-revenue injectable franchises, and it rewards reps who are as comfortable talking practice growth and marketing as clinical outcomes. The trade is cyclicality: because it is cash-pay and consumer-driven, aesthetics feels good times and bad more sharply than reimbursed categories.
If you like a fast, consumer-flavored market and selling to entrepreneurial practices, aesthetics is one of the most distinctive lanes in the field.
Key Takeaways
- Aesthetics is largely cash-pay and consumer-driven, sold to derms, plastic surgeons, and med spas, not hospitals.
- The device market alone is growing from about $22 billion toward $38 billion by 2029.
- AbbVie's Allergan Aesthetics leads (Botox, Juvederm, CoolSculpting); Galderma is the fast-rising pure-play at about $5.2 billion.
- Energy-device makers like Candela, InMode, Solta, and Sciton supply the hardware side.
- The market is cyclical and cash-pay, so it swings more with consumer confidence than reimbursed categories.
Frequently Asked Questions
What companies make aesthetic and dermatology devices?
The category spans injectables and energy devices. AbbVie's Allergan Aesthetics (Botox, Juvederm, CoolSculpting), Galderma (Restylane, Dysport, Sculptra), and Merz (Xeomin, Radiesse, Ultherapy) lead injectables and biostimulators, while Candela, InMode, Solta Medical, and Sciton supply energy-based devices like lasers and radiofrequency platforms.
Is medical aesthetics sales a good career?
It can be lucrative and fast-paced, especially in recurring-revenue injectable lines, and it rewards reps comfortable selling practice growth as much as clinical outcomes. The main trade-off is cyclicality: because aesthetics is cash-pay and consumer-driven, it swings more sharply with the economy than reimbursed categories.
Who is the largest aesthetics company?
AbbVie, through Allergan Aesthetics, is the largest, home to Botox Cosmetic, the Juvederm filler collection, and CoolSculpting. Galderma is the fast-growing pure-play challenger at about $5.2 billion in sales, gaining injectable share.
How is aesthetics sales different from other medical sales?
Aesthetics is mostly elective and cash-pay, so demand is driven by consumers and marketing rather than insurance coverage, and the customers are private practices and med spas rather than hospitals. Reps often sell business growth and recurring consumables like injectables, not just devices.
Related Reading
- The Medical Device Companies Every New Rep Should Know
- Capital vs. Consumable Sales in Medical Devices: What's the Difference?
- Is Medical Sales a Good Career? An Honest Look
About This Series
This guide is part of Vocari Intelligence, The Lobby’s series on how the medical sales business actually works, built from company financials and market data.
Drawn to aesthetics? Set your parameters once on [Vocari](https://www.myvocari.com) and let matching roles come to you.